Onconetix, Inc. (NASDAQ:ONCO) Stock Short Interest Report for September

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 489,621 shares, a growth of 261.8% from the September 15th total of 135,320 shares. Based on an average trading volume of 10,331,807 shares, the short-interest ratio is currently 0.0 days. Approximately 11.2% of the shares of the stock are sold short.

Analyst Ratings Changes

ONCO has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. Wall Street Zen raised Onconetix from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Onconetix has an average rating of “Sell”.

Onconetix Stock Performance

ONCO stock traded down $0.03 during trading on Friday, hitting $0.62. The stock had a trading volume of 1,058,382 shares, compared to its average volume of 8,318,602. The company’s 50 day moving average price is $0.77 and its two-hundred day moving average price is $3.64. Onconetix has a 1-year low of $0.58 and a 1-year high of $207.00. The stock has a market cap of $3.25 million, a price-to-earnings ratio of 0.00 and a beta of 2.61.

Onconetix (NASDAQ:ONCO) last announced its earnings results on Thursday, August 13th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4,505.00) by $4,503.72. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million.

Onconetix Company Profile

Onconetix, Inc is a biotechnology company focused on developing and commercializing products for men’s health and oncology. The company’s activities center on therapies and diagnostic tools intended to address conditions affecting the prostate and related areas of healthcare.

Onconetix’s lead commercial product is ENTADFI, an oral prescription treatment for the signs and symptoms of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate. ENTADFI combines tadalafil and finasteride and is designed to provide both rapid symptom relief and longer-term reduction of prostate-related urinary symptoms.

The company also has interests in prostate cancer diagnostics, including Proclarix, a blood-based test intended to help assess the likelihood of clinically significant prostate cancer in men with elevated prostate-specific antigen levels.